6Van der Elst J, van den Abbeel E, Jacobs R, et al. Effect of 1,2-propanediol and dimethylsulphoxide on the meiotic spindle of the mouse oocytes[ J]. Hum Reprod, 1988, 3:960-967
3Lewkowich LP,HayGlass KT.Endogenous IFN-gamma and IL-18 production directly limit induction of type2 immunity in vivo[J].Eur J Immunol,2002,32(12):3536-3545.
4McMilanR.Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura[J].Semin Hematol,2000,37 (3):239-248.
5Haggqvist B,Hultman P.Effects of deviating the Th2-response in murine mercury-induced autoimmunity towards a Th1-response[J].Clin Exp Immunol,2003,134(2):202-209.
6Andersson PO,Olsson A,Wadenvik H.Reduced transforming growth factor-betal production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura[J].Br Haematol,2002,116(4):862-867.
7Semple JW. T cell and cytokine abnormalities in patients with autoimmune thrombocytopenic purpura[J]. Transfus Apheresis Sci, 2003, 28: 237-242.
8Thornton AM, Shevach EM. CD4^+CD25^+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting IL-2 production[J]. J Exp Med, 1998,188: 287-296.
9Hori S, Takahashi T, Sakaguchi S. Contol of autoimmunity by naturally arising regulatory CD4^4T cells[J]. Adv Immunol, 2003,81:331-371.
10Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic self-tole-rance maintainted by CD4^+CD25^+ naturally anergic and suppressive T cells:induction of autoimmune disease by breaking their anergic/suppressive state[J]. Int Immunol, 1998, 10: 1969-1980.
1Du X,Williams DA.Interleukin-11: review of molecular, cell biology and clinicle use. Blood . 1997
2沈晓明;王卫平.儿科学.7版7版[M].北京:人民卫生出版社,2008364-367.
3Ishida Y,Kowata S. The cutting-edge of medicine:The patho-physiology and development of therapy in immune thrombocytopenia[J].Nihon Naika Gakkai Zasshi,2012,(02):472-479.
4Dardalhon V, Awasthi A ,Kwon H ,et al. IL-.4 inhibits TGF-beta in- duced Foxp3 + T cells and, together with TGF-beta, generates IL-9 + IL-IO + Foxp3 (-) effector T cells [ J]. Nat Immunol,2008,9 (12) : 1347-1355. DOI: 10. 10 38/ni. 1677.
5Veldhoen M, Uyttenhove C, Van S J, et al. Transforming growth fac- tor-beta reprograms the differentiation of T helper 2 cells and pro- motes an interleukin 9-producing subset[J]. Nat Immunol,2008, 9(12):1341-1346.DOI:10.1038/ni.1659.
6Portielje JE,Westendorp PG,Kluin-Nelemans HC,et al.Motbidity and Mortality in adults with idlopathie thrombocytopenle purpura[J].Blood,2001;97(9):2549.
7Zver S,Zupan IP,Cernelc P.Cyclosporin A as an immunosuppressive treatment modality for patients with refractory autoimmune thrombocytopenic purpura after splenectomy failure[J].Int J Hematol,2006;83(7):238-42.
8Arnold DM,Nazi I,Santos A,et al.Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic pupura[J].Blood,2010;115(8):29-31.
9Provan D,Stasir R,Newland AC,et al.International consensus report on the investigation and management of primary immune thrombocytopenia[J].Blood,2010;115(2):168-86.
10Tamary H,Roganovic J,Chitlur M,et al.Consensus Paper ICIS exper Meeting Basel 2009 treatment milestones in immune thrombocytopenia[J].Ann Hematol,2010;89(Suppl 1):5-10.
